Omnibrx Biotechnologies Profile
Key Indicators
- Authorised Capital ₹ 0.80 M
as on 19-12-2024
- Paid Up Capital ₹ 0.24 M
as on 19-12-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.13 Cr
as on 19-12-2024
- Revenue 64.80%
(FY 2022)
- Profit 150.04%
(FY 2022)
- Ebitda 206.29%
(FY 2022)
- Net Worth 121.67%
(FY 2022)
- Total Assets 90.67%
(FY 2022)
About Omnibrx Biotechnologies
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.80 M and a paid-up capital of Rs 0.24 M.
The company currently has active open charges totaling ₹1.13 Cr.
Ravindra Patel and Heenaben Patel serve as directors at the Company.
- CIN/LLPIN
U29306GJ2016PTC092297
- Company No.
092297
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 2016
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Omnibrx Biotechnologies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravindra Patel  | Managing Director | 02-Jun-2016 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Heenaben Patel | Director | 27-Sep-2016 | Current |
Financial Performance of Omnibrx Biotechnologies.
Omnibrx Biotechnologies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 64.8% increase. The company also saw a substantial improvement in profitability, with a 150.04% increase in profit. The company's net worth Soared by an impressive increase of 121.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omnibrx Biotechnologies?
In 2021, Omnibrx Biotechnologies had a public holding of 20.74%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 Aug 2021 | ₹1.25 M | Open |
Sidbi Creation Date: 16 Aug 2019 | ₹1.00 Cr | Open |
How Many Employees Work at Omnibrx Biotechnologies?
Omnibrx Biotechnologies has a workforce of 57 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omnibrx Biotechnologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omnibrx Biotechnologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
